Advertisement

Topics

Pharnext SA ALPHA Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

05:58 EDT 25 Sep 2017 | BioPortfolio Reports

Summary

Pharnext SA Pharnext is a biopharmaceutical company that develops new treatments for severe orphan and common neurological disorders. The company's proprietary research and development platform is based on network pharmacology that uses wide genomic data to identify thousands of molecules related to specific diseases and facilitates the development of synergistic combinations of drugs pleodrugs. Pharnext's lead pleodrugs in clinical development include PXT3003, for CharcotMarieTooth disease type 1A currently in Phase III trials; and PXT864, for Alzheimer's disease and other neurological indications including Parkinson's disease and amyotrophic lateral sclerosis ALS currently in Phase II trials. The company also identifies and develops synergistic combinations of repositioned drugs at small doses. Pharnext is headquartered in IssyLesMoulineaux, France.

Pharnext SA Key Recent Developments

Jun 20,2017: Pharnext to Showcase Pioneering PLEOTHERAPY RD Platform at 6th Annual Drug Repositioning, Repurposing and Rescue Conference
Apr 26,2017: Pharnext Reports Year End 2016 Financial Results
Feb 02,2017: Pharnext Announces Findings Evaluating CharcotMarieTooth Neuropathy Score
Jul 26,2016: Pharnext Announces the Appointment of Rene Goedkoop as Chief Medical Officer and Francois Chamoun as General Counsel
Jun 01,2016: Pharnext announces the nomination of a new Board of Directors chaired by Michel de Rosen

This comprehensive SWOT profile of Pharnext SA provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Pharnext SA including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends.

The profile contains critical company information including*, x000D
x000D
Business description A detailed description of the company's operations and business divisions.x000D
Corporate strategy Analyst's summarization of the company's business strategy.x000D
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D
Company history Progression of key events associated with the company.x000D
Major products and services A list of major products, services and brands of the company.x000D
Key competitors A list of key competitors to the company.x000D
Key employees A list of the key executives of the company.x000D
Executive biographies A brief summary of the executives' employment history.x000D
Key operational heads A list of personnel heading key departments/functions.x000D
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D
Key manufacturing facilities A list of key manufacturing facilities of the company.x000D
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D
x000D
Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,x000D
x000D
You get detailed information about the company and its operations to identify potential customers and suppliers.x000D
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D
x000D
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D
x000D
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D
x000D
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D
x000D
Gain key insights into the company for academic or business research.x000D
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Original Article: Pharnext SA ALPHA Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

NEXT ARTICLE

More From BioPortfolio on "Pharnext SA ALPHA Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300"

Quick Search
Advertisement
 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...